WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006019497) SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/019497    International Application No.:    PCT/US2005/021848
Publication Date: 23.02.2006 International Filing Date: 17.06.2005
IPC:
C07D 333/58 (2006.01), C07D 409/04 (2006.01), C07D 417/04 (2006.01), A61K 31/381 (2006.01)
Applicants: NEUROCRINE BIOSCIENCES, INC. [US/US]; 12790 El Camino Real, San Diego, California 92130 (US) (For All Designated States Except US).
BEATON, Graham [GB/US]; (US) (For US Only).
MOREE, Wilna (Willy), J. [NL/US]; (US) (For US Only).
JOVIC, Florence [FR/US]; (US) (For US Only).
COON, Timothy [US/US]; (US) (For US Only).
YU, Jinghua [CN/US]; (US) (For US Only)
Inventors: BEATON, Graham; (US).
MOREE, Wilna (Willy), J.; (US).
JOVIC, Florence; (US).
COON, Timothy; (US).
YU, Jinghua; (US)
Agent: HERMANNS, Karl, R.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, Washington 98104-7092 (US)
Priority Data:
60/580,639 17.07.2004 US
Title (EN) SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO
(FR) COMPOSES SOMNIFERES ET PROCEDES ASSOCIES
Abstract: front page image
(EN)Compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts, esters and solvates thereof, wherein R1, R2, R3a, R3b, L1, L2 and n are as defined herein. Such compounds generally function as H1 receptor ligands, and thus have utility as sleep inducing agents. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
(FR)L'invention porte sur des composés représentés par la formule (I) contenant des stéréoisomères, des promédicaments, et des sels pharmaceutiquement acceptables, des esters, et des solvants de ceux-ci, R1, R2, R3a, R3b, L1, L2 et n étant tels que définis ci-après. Ces composés servent généralement de ligands du récepteur H1, et sont donc utiles en tant qu'agents somnifères. L'invention porte aussi sur des compositions pharmaceutiques contenant un composé représenté par la structure (I), ainsi que sur des procédés d'utilisation associés.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)